Fmr LLC Grows Holdings in Sarepta Therapeutics Inc (NASDAQ:SRPT)

FMR LLC boosted its position in Sarepta Therapeutics Inc (NASDAQ:SRPT) by 6.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 10,565,177 shares of the biotechnology company’s stock after acquiring an additional 677,947 shares during the quarter. FMR LLC owned 15.81% of Sarepta Therapeutics worth $1,152,977,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in SRPT. Vanguard Group Inc lifted its holdings in Sarepta Therapeutics by 3.3% in the third quarter. Vanguard Group Inc now owns 5,384,899 shares of the biotechnology company’s stock worth $869,715,000 after buying an additional 170,999 shares during the period. BlackRock Inc. increased its stake in shares of Sarepta Therapeutics by 0.8% during the fourth quarter. BlackRock Inc. now owns 4,845,231 shares of the biotechnology company’s stock valued at $528,758,000 after purchasing an additional 36,972 shares in the last quarter. venBio Select Advisor LLC increased its stake in shares of Sarepta Therapeutics by 35.1% during the fourth quarter. venBio Select Advisor LLC now owns 1,275,000 shares of the biotechnology company’s stock valued at $139,141,000 after purchasing an additional 331,500 shares in the last quarter. Eagle Asset Management Inc. increased its stake in shares of Sarepta Therapeutics by 2.0% during the fourth quarter. Eagle Asset Management Inc. now owns 1,088,556 shares of the biotechnology company’s stock valued at $118,794,000 after purchasing an additional 21,238 shares in the last quarter. Finally, Geode Capital Management LLC increased its stake in shares of Sarepta Therapeutics by 11.4% during the fourth quarter. Geode Capital Management LLC now owns 658,753 shares of the biotechnology company’s stock valued at $71,889,000 after purchasing an additional 67,601 shares in the last quarter. 95.68% of the stock is currently owned by institutional investors and hedge funds.

SRPT stock traded down $2.09 on Friday, hitting $116.64. The company had a trading volume of 2,391,551 shares, compared to its average volume of 1,240,611. Sarepta Therapeutics Inc has a 12-month low of $74.51 and a 12-month high of $176.50. The company has a current ratio of 8.21, a quick ratio of 7.49 and a debt-to-equity ratio of 0.41. The stock has a market capitalization of $8.32 billion, a P/E ratio of -21.36 and a beta of 2.04.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its earnings results on Wednesday, February 27th. The biotechnology company reported ($2.05) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.08) by ($0.97). Sarepta Therapeutics had a negative return on equity of 36.73% and a negative net margin of 120.22%. The company had revenue of $84.40 million during the quarter, compared to analysts’ expectations of $84.83 million. During the same quarter in the prior year, the business posted ($0.37) EPS. The company’s revenue for the quarter was up 47.3% compared to the same quarter last year. As a group, equities analysts predict that Sarepta Therapeutics Inc will post -4.71 earnings per share for the current year.

In other news, CFO Sandesh Mahatme sold 65,000 shares of Sarepta Therapeutics stock in a transaction on Thursday, January 31st. The shares were sold at an average price of $130.23, for a total transaction of $8,464,950.00. Following the transaction, the chief financial officer now owns 14,118 shares in the company, valued at approximately $1,838,587.14. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP David T. Howton sold 30,000 shares of Sarepta Therapeutics stock in a transaction on Friday, February 1st. The stock was sold at an average price of $140.00, for a total transaction of $4,200,000.00. Following the transaction, the senior vice president now owns 31,196 shares in the company, valued at approximately $4,367,440. The disclosure for this sale can be found here. Insiders have sold a total of 160,000 shares of company stock worth $22,089,950 in the last quarter. Corporate insiders own 7.90% of the company’s stock.

A number of brokerages have weighed in on SRPT. BTIG Research set a $190.00 target price on shares of Sarepta Therapeutics and gave the company a “buy” rating in a research note on Friday, December 28th. Svb Leerink reaffirmed an “outperform” rating on shares of Sarepta Therapeutics in a research note on Tuesday, March 5th. Janney Montgomery Scott set a $200.00 target price on shares of Sarepta Therapeutics and gave the company a “buy” rating in a research note on Tuesday, January 8th. Zacks Investment Research raised shares of Sarepta Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, January 23rd. Finally, HC Wainwright set a $267.00 target price on shares of Sarepta Therapeutics and gave the company a “buy” rating in a research note on Friday, January 4th. One analyst has rated the stock with a sell rating, three have given a hold rating, twenty-six have given a buy rating and one has given a strong buy rating to the stock. Sarepta Therapeutics presently has an average rating of “Buy” and an average price target of $191.14.

COPYRIGHT VIOLATION NOTICE: This piece was first posted by Baseball Daily News and is the sole property of of Baseball Daily News. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of US & international copyright and trademark legislation. The correct version of this piece can be read at https://www.baseballdailydigest.com/news/2019/04/21/fmr-llc-has-1-15-billion-position-in-sarepta-therapeutics-inc-srpt.html.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare diseases. The company offers EXONDYS 51, a disease-modifying therapy for duchenne muscular dystrophy (DMD). Its products pipeline include Golodirsen, a product candidate that binds to exon 53 of dystrophin pre-mRNA, which results in exclusion or skipping of exon during mRNA processing in patients with genetic mutations; and Casimersen, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the DMD gene.

Featured Story: Asset Allocation Models, Which is Right For You?

Institutional Ownership by Quarter for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.